hrp0095fc5.1 | Adrenals and HPA Axis | ESPE2022
Bueno Ana C
, da Silva Jr Rui M P
, Stecchini Mônica F
, Cardinalli Izilda A
, Junqueira Thais
, A Scrideli Carlos
, AF Molina Carlos
, Tucci Silvio
, Coeli-Lacchini Fernanda B
, Moreira Ayrton C
, Ramalho Leandra NZ
, Brandalise Silvia R
, Yunes José A
, Vêncio Ricardo ZN
, de Castro Margaret
, Antonini Sonir R
Children diagnosed with adrenocortical tumors (ACT) have variable prognosis depending on disease presentation at diagnosis. Available therapeutic options render excellent outcome for a subset of patients, but limited improvement in the survival of those diagnosed with non-localized/advanced disease. ACT DNA methylation was recently demonstrated to be a robust and independent prognostic biomarker. Aiming to identify potential therapeutic targets for these children, we compared ...